Janux Therapeutics (JANX) News Today $41.26 -2.45 (-5.61%) (As of 09/6/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 Time Period September 6 at 5:33 PM | benzinga.comNavigating 5 Analyst Ratings For Janux TherapeuticsSeptember 6 at 1:30 PM | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Shares Gap Up to $43.71Janux Therapeutics (NASDAQ:JANX) Shares Gap Up to $43.71September 6 at 12:32 PM | seekingalpha.comJanux initiated at Stifel with Buy on upcoming data updateSeptember 6 at 8:08 AM | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Now Covered by Stifel NicolausStifel Nicolaus started coverage on shares of Janux Therapeutics in a report on Friday. They issued a "buy" rating and a $70.00 price target for the company.September 6 at 7:56 AM | marketbeat.comOvata Capital Management Ltd Decreases Stake in Janux Therapeutics, Inc. (NASDAQ:JANX)Ovata Capital Management Ltd lessened its stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 50.0% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 20,000 shares of the company's stock afterSeptember 1, 2024 | marketbeat.comJanux Therapeutics, Inc. (NASDAQ:JANX) Short Interest UpdateJanux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) was the recipient of a large decrease in short interest in the month of August. As of August 15th, there was short interest totalling 3,250,000 shares, a decrease of 11.2% from the July 31st total of 3,660,000 shares. Approximately 8.6% of the shares of the company are sold short. Based on an average trading volume of 681,000 shares, the days-to-cover ratio is currently 4.8 days.September 1, 2024 | finance.yahoo.comJanux Therapeutics, Inc. (JANX)September 1, 2024 | seekingalpha.comJanux Therapeutics: Buoyed By Buyout SpeculationSeptember 1, 2024 | americanbankingnews.comJanux Therapeutics (NASDAQ:JANX) Trading Up 5.3%August 30, 2024 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Trading 5.3% Higher Janux Therapeutics (NASDAQ:JANX) Stock Price Up 5.3%August 21, 2024 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Shares Down 3.8% Janux Therapeutics (NASDAQ:JANX) Stock Price Down 3.8%August 21, 2024 | marketbeat.comQ3 2024 Earnings Forecast for Janux Therapeutics, Inc. Issued By HC Wainwright (NASDAQ:JANX)Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) - Research analysts at HC Wainwright reduced their Q3 2024 earnings per share estimates for shares of Janux Therapeutics in a report released on Monday, August 19th. HC Wainwright analyst S. Ramakanth now expects that the company will earn ($0.August 18, 2024 | marketbeat.comJanux Therapeutics, Inc. (NASDAQ:JANX) Receives Average Recommendation of "Moderate Buy" from AnalystsJanux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the eight research firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating and seven have given a buy rating tAugust 16, 2024 | marketbeat.comSG Americas Securities LLC Makes New $1.45 Million Investment in Janux Therapeutics, Inc. (NASDAQ:JANX)SG Americas Securities LLC acquired a new stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 34,664 shares of the company's stock,August 14, 2024 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Trading Up 4.5%Janux Therapeutics (NASDAQ:JANX) Trading 4.5% HigherAugust 13, 2024 | marketbeat.comPrice T Rowe Associates Inc. MD Invests $739,000 in Janux Therapeutics, Inc. (NASDAQ:JANX)Price T Rowe Associates Inc. MD purchased a new stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 19,596 shares of the company's stock, valued aAugust 9, 2024 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Price Target Cut to $42.00Scotiabank decreased their price target on Janux Therapeutics from $47.00 to $42.00 and set a "sector perform" rating for the company in a research note on Friday.August 9, 2024 | markets.businessinsider.comWedbush Reaffirms Their Buy Rating on Janux Therapeutics Inc (JANX)August 8, 2024 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Issues Earnings Results, Beats Expectations By $0.20 EPSJanux Therapeutics (NASDAQ:JANX - Get Free Report) issued its quarterly earnings results on Wednesday. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.20. The firm had revenue of $8.90 million during the quarter, compared to analyst estimates of $0.77 million. Janux Therapeutics had a negative net margin of 762.92% and a negative return on equity of 13.49%. The company's revenue for the quarter was up 709.1% compared to the same quarter last year.August 8, 2024 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Stock Rating Reaffirmed by Cantor FitzgeraldCantor Fitzgerald restated an "overweight" rating and set a $100.00 target price on shares of Janux Therapeutics in a research report on Thursday.August 8, 2024 | markets.businessinsider.comTD Cowen Keeps Their Buy Rating on Janux Therapeutics Inc (JANX)August 7, 2024 | finance.yahoo.comJanux Therapeutics Reports Second Quarter 2024 Financial Results and Business HighlightsAugust 7, 2024 | marketbeat.comVanguard Group Inc. Has $51.13 Million Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX)Vanguard Group Inc. boosted its holdings in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 38.6% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,357,960 shares of the company's stock after purchasingAugust 2, 2024 | marketbeat.com16,183 Shares in Janux Therapeutics, Inc. (NASDAQ:JANX) Bought by Virtu Financial LLCVirtu Financial LLC bought a new stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 16,183 shares of the company's stock, valued at approximately $July 31, 2024 | marketbeat.comJanux Therapeutics, Inc. (NASDAQ:JANX) Shares Purchased by Janus Henderson Group PLCJanus Henderson Group PLC raised its stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 1.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,965,546 shares of the company's stock after purchasingJuly 23, 2024 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Trading Down 4.3%Janux Therapeutics (NASDAQ:JANX) Shares Down 4.3%July 22, 2024 | businesswire.comJanux Therapeutics Announces Updates to Board of DirectorsJuly 20, 2024 | marketbeat.comLord Abbett & CO. LLC Takes Position in Janux Therapeutics, Inc. (NASDAQ:JANX)Lord Abbett & CO. LLC bought a new stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 542,373 shares of the company's stock, valued at approJuly 20, 2024 | investing.comJanux Therapeutics Inc (JANX)July 16, 2024 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Stock Price Up 10.8%Janux Therapeutics (NASDAQ:JANX) Stock Price Up 10.8%July 11, 2024 | marketbeat.comAllspring Global Investments Holdings LLC Sells 19,915 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)Allspring Global Investments Holdings LLC trimmed its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 75.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investorJuly 7, 2024 | marketbeat.comCapstone Investment Advisors LLC Acquires Shares of 52,300 Janux Therapeutics, Inc. (NASDAQ:JANX)Capstone Investment Advisors LLC acquired a new stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 52,300 shares of the compaJuly 2, 2024 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Stock Price Down 4.6%Janux Therapeutics (NASDAQ:JANX) Shares Down 4.6%June 29, 2024 | marketbeat.comJanux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Rating of "Moderate Buy" by BrokeragesShares of Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) have earned an average rating of "Moderate Buy" from the eight research firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and seven have aJune 26, 2024 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Stock Price Down 4%Janux Therapeutics (NASDAQ:JANX) Shares Down 4%June 26, 2024 | seekingalpha.comJanux Therapeutics: Promising T-Cell Engager Platform In Cancer TherapyJune 21, 2024 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Shares Gap Up to $40.30Janux Therapeutics (NASDAQ:JANX) Shares Gap Up to $40.30June 18, 2024 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Trading 4.2% Higher Janux Therapeutics (NASDAQ:JANX) Trading Up 4.2%June 6, 2024 | insidertrades.comJanux Therapeutics, Inc. (NASDAQ:JANX) Major Shareholder Sells $37,081,025.25 in StockJune 5, 2024 | marketbeat.comJanux Therapeutics, Inc. (NASDAQ:JANX) Major Shareholder Ventures Xi L.P. Avalon Sells 677,279 SharesJanux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) major shareholder Ventures Xi L.P. Avalon sold 677,279 shares of the stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $54.75, for a total value of $37,081,025.25. Following the completion of the sale, the insider now directly owns 3,271,216 shares of the company's stock, valued at $179,099,076. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Large shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.June 4, 2024 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Stock Price Down 7%Janux Therapeutics (NASDAQ:JANX) Trading Down 7%June 4, 2024 | marketbeat.com51,548 Shares in Janux Therapeutics, Inc. (NASDAQ:JANX) Acquired by Janney Montgomery Scott LLCJanney Montgomery Scott LLC purchased a new stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 51,548 shares of the company's stock, valued at approxJune 4, 2024 | marketbeat.comJanux Therapeutics, Inc. (NASDAQ:JANX) Receives Average Recommendation of "Moderate Buy" from BrokeragesShares of Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) have been assigned an average rating of "Moderate Buy" from the eight analysts that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and seven have given a buy ratingMay 14, 2024 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Trading Down 3.1%Janux Therapeutics (NASDAQ:JANX) Shares Down 3.1%May 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Valneva (VALN), Janux Therapeutics Inc (JANX) and Kymera Therapeutics (KYMR)May 13, 2024 | markets.businessinsider.comAnalyst Ratings For Janux TherapeuticsMay 13, 2024 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Price Target Raised to $63.00 at HC WainwrightHC Wainwright raised their price target on Janux Therapeutics from $50.00 to $63.00 and gave the stock a "buy" rating in a research note on Monday.May 10, 2024 | marketbeat.comQ2 2024 EPS Estimates for Janux Therapeutics, Inc. Cut by William Blair (NASDAQ:JANX)Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) - Stock analysts at William Blair reduced their Q2 2024 earnings estimates for shares of Janux Therapeutics in a research note issued on Tuesday, May 7th. William Blair analyst M. Phipps now expects that the company will earn ($0.21) per shareMay 9, 2024 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Given "Overweight" Rating at Cantor FitzgeraldCantor Fitzgerald reissued an "overweight" rating and issued a $100.00 price objective on shares of Janux Therapeutics in a research note on Thursday.May 8, 2024 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Shares Down 11.5% Janux Therapeutics (NASDAQ:JANX) Stock Price Down 11.5% Get Janux Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JANX and its competitors with MarketBeat's FREE daily newsletter. Email Address Tim Sykes’ Urgent Trade Alert: “Make this move now” (Ad)WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race… Click here to see a unique election-year trade JANX Media Mentions By Week JANX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. JANX News Sentiment▼0.640.55▲Average Medical News Sentiment JANX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. JANX Articles This Week▼102▲JANX Articles Average Week Get Janux Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JANX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: PRAX News Today SRRK News Today IGMS News Today HARP News Today FHTX News Today OCGN News Today PSTX News Today NKTR News Today CRBU News Today RPTX News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:JANX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Janux Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Janux Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.